cbdMD (YCBD) Fundamental Analysis: Revenue, Earnings & Valuation

1.37 / 10

Underperform

Fundamentally the stock is underperforming, with a 1.4/10 score. Key issues include negative operating cash flow (-7.57%), a -60.55% ROE, poor net profit margin (-10.64%), high current liabilities (100% of total), and a long operating cycle, outweighing a modest Asset‑MV edge.

Analysis Checks(1/10)

Revenue-MV

Value0.63

Score0/3

Weight16.33%

1M Return-10.91%

Shareholders’ equity attributable to parent company / Total liabilities (%)

Value2.26

Score1/3

Weight8.05%

1M Return-4.23%

Operating cycle

Value155.35

Score1/3

Weight8.34%

1M Return-6.27%

Net cash flow from operating activities / Operating revenue (%)

Value-7.57

Score0/3

Weight12.34%

1M Return-8.07%

Current liabilities / Total liabilities (%)

Value100.00

Score0/3

Weight11.80%

1M Return-8.17%

Net profit margin (%)

Value-10.63

Score1/3

Weight7.91%

1M Return-4.38%

ROE (diluted) (%)

Value-60.55

Score0/3

Weight14.56%

1M Return-8.07%

Net profit / Total operating revenue (%)

Value-10.63

Score1/3

Weight7.91%

1M Return-4.38%

Asset-MV

Value-0.55

Score2/3

Weight1.32%

1M Return-0.65%

Cash-MV

Value0.02

Score1/3

Weight11.44%

1M Return-7.96%

Is YCBD fundamentally strong?

YCBD scores 1.37/10 on fundamentals and holds a Premium valuation at present. Backed by its -4.00% ROE, -12.25% net margin, -2.02 P/E ratio, 0.83 P/B ratio, and 105.63% earnings growth, these metrics solidify its Underperform investment rating.